X0306 4 2021-04-15 0 0001601830 RECURSION PHARMACEUTICALS, INC. RXRX 0001856094 Borgeson Blake C/O RECURSION PHARMACEUTICALS 41 S. RIO GRANDE STREET SALT LAKE CITY UT 84101 1 0 0 0 Common Stock 2021-04-16 4 A 0 6250 0.00 A 6765304 D Stock Option (Right to Buy) 18.00 2021-04-15 4 A 0 12500 0.00 A 2031-04-14 Common Stock 12500 12500 D Series A Preferred Stock 0.00 Common Stock 378309 378309 D Series A-1 Preferred Stock 0.00 Common Stock 544743 544743 D Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Each share of Series C Preferred Stock shall automatically convert into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. The shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of common stock of the Issuer, with all such shares being received on the earlier of April 16, 2022 or the Issuer's first annual meeting of stockholders. The option becomes exercisable as to all of the shares subject to the option on the earlier of April 15, 2022 and the Issuer's first annual stockholder meeting. /s/ Nathan Hatfield, attorney-in-fact 2021-04-19